BeOne Medicines Ltd. - 24 Sep 2021 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Reporting relationship: 10%+ Owner
Issuer ticker: LPTX
Reported as of: 24 Sep 2021
Net transaction value: +$7,249,830
SEC form: 4
Accepted by SEC: 28 Sep 2021, 17:48:31 UTC
Source filing: View source filing
Reporting owner signature: BeiGene, Ltd. /s/ Scott A. Samuels, SVP, General Counsel

Key filing fact

BeOne Medicines Ltd. filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 28 Sep 2021.

Key facts

This page summarizes BeOne Medicines Ltd.'s Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Sep 2021, 17:48.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$7,249,830.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LPTX transaction

Common Stock

Purchase

Transaction value: $7,249,830
Shares: +2,543,800
Change %: +53%
Price: $2.85
Shares after: 7,348,437
Date: 24 Sep 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On September 24, 2021, BeiGene, Ltd. purchased 2,543,800 shares of common stock of the Issuer for $2.85 per share pursuant to an underwritten public offering.